Efficacy and Safety of SGLT2 inhibitors in patients with type 1 diabete.

Efficacy and Safety of SGLT2 inhibitors in patients with type 1 diabete. - SGLT2i in T1DM,Sapporo

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044317

Enrollment

200

Registered

2021-05-28

Start date

2021-01-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 1 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with type 1 diabetes who are treated in Hokkaido University Hospital or collaborate hospitals from December 2018. 2) Patients with type 1 diabetes who have been treated with SGLT2 inhibitors.

Exclusion criteria

Exclusion criteria: Patients who were thought to be inappropriate to enter this study for some reasons by physician's judgments

Design outcomes

Primary

Measure	Time frame
Changes in HbA1c and weight	—

Secondary

Measure	Time frame
1. Blood and urine test (Plasma glucose, eGFR, UACR, UA, AST, ALT, Hb, etc) 2. Body mass index 3. Blood pressure 4. Insulin dose 5. Diabetic complication 6. Subgroup analysis depends on baseline (age, sex, weight, BMI, kidney function, etc) 7. Adverse events/Discontinuation of medication	—

Countries

Japan

Contacts

Public ContactHideaki Miyoshi

Hokkaido University Faculty of Medicine and Graduate School of Medicine Division of Diabetes and Obesity

hmiyoshi@med.hokudai.ac.jp011-706-8192

Outcome results